Evaluating Genetic Modifiers of Cutaneous Neurofibromas in Adults With Neurofibromatosis Type 1
NCT ID: NCT04941027
Last Updated: 2025-12-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
1046 participants
OBSERVATIONAL
2021-05-07
2025-11-24
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study of Disease Severity in Adults With Neurofibromatosis Type 1 (NF1)
NCT00111384
Modifying Genes in Neurofibromatosis 1
NCT01650142
Adaptation and Quality of Life Among Adults With Neurofibromatosis Type I
NCT00684398
Microarray CGH Analysis of Circulating Tumoral Plasma DNA in NF1 Patients With MPNSTs
NCT01218152
Genetic Evaluation of NF1 and Scoliosis Patients
NCT01776125
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
CROSS_SECTIONAL
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* NF type 1 diagnosed using clinical criteria.
* At least one neurofibroma present at time of enrollment.
* Patient able to read and understand consent form (or equivalent translation) and able to give consent.
* Patient able and willing to complete all study procedures.
40 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Johns Hopkins University
OTHER
University of California, San Francisco
OTHER
Stanford University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Kavita Sarin
Assistant Professor of Medicine
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Kavita Sarin, MD PhD
Role: PRINCIPAL_INVESTIGATOR
Stanford University
Jaishri Blakely, MD
Role: PRINCIPAL_INVESTIGATOR
Johns Hopkins University
Carlos Romo, MD
Role: PRINCIPAL_INVESTIGATOR
Johns Hopkins University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Johns Hopkins University School of Medicine
Baltimore, California, United States
Stanford University
Redwood City, California, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MZ-0053000
Identifier Type: OTHER
Identifier Source: secondary_id
SPO: 200898
Identifier Type: OTHER_GRANT
Identifier Source: secondary_id
53000
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.